RxDoctor Payments Data

Vinicio de Jesus Perez, MD

Pulmonary Disease · Palo Alto, CANPI 1043321581

Payments from drug & device makers

$116,150in general payments, 2019–2025

Across 155 payments — averaging $749.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$41K
  • United Therapeutics Corporation$38K
  • Merck$23K
  • Actelion Pharmaceuticals US, Inc.$9K
  • Actelion Pharmaceuticals, Ltd$5K
  • Vertex$810
  • plus $26 from 1 others

What the payments were for

  • Consulting fees$98,12284%
  • Travel & lodging$11,46710%
  • Food & beverage$6,5436%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,150 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$11,548
Medicare patients
44
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan77$949,484
Tyvaso DpiTreprostinil38$888,690
UptraviSelexipag13$278,118
Orenitram ErTreprostinil Diolamine36$206,241
LetairisAmbrisentan15$174,807
Ambrisentan17$113,603
Sildenafil Citrate64$8,562
Bumetanide11$997
Tadalafil23$798
Potassium Chloride11$429
Furosemide22$62
Pantoprazole Sodium11$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$8,580$1,227,60290 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →